Advances in antiplatelet therapy for acute coronary syndromes
Hussain Contractor1, Neil Ruparelia
1Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Headley Way, Oxford, Oxfordshire, UK. hussain.contractor@cardiov.ox.ac.uk
Insights
New antiplatelet agents offer improved outcomes for acute coronary syndromes but require careful patient selection to manage bleeding risks. This review details the evolving landscape of antiplatelet therapy.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Acute coronary syndromes (ACS) represent a significant healthcare burden globally.
- Early pharmacological intervention, particularly antiplatelet therapy, is critical for reducing ACS morbidity and mortality.
- Aspirin and clopidogrel have been standard treatments, but newer agents are emerging.
Purpose of the Study:
- To review the evolving field of antiplatelet therapy for ACS.
- To provide an overview of newer, more potent antiplatelet agents.
- To discuss the relative risks and benefits of these emerging therapies.
Main Methods:
- Literature review of current and developing antiplatelet agents for ACS.
- Analysis of clinical data regarding efficacy and safety profiles.
- Comparative assessment of traditional versus novel antiplatelet medications.
Main Results:
- Newer antiplatelet agents demonstrate superior anti-ischaemic properties and improved patient outcomes.
- Some novel agents necessitate increased clinical vigilance and precise patient selection due to bleeding risks.
- The landscape of ACS management is shifting towards more potent antiplatelet strategies.
Conclusions:
- The introduction of novel antiplatelet agents is transforming ACS treatment.
- Balancing enhanced efficacy with potential bleeding complications is key for optimal patient care.
- Clinicians must be prepared for the imminent widespread use of these advanced therapies.
Abstract:
Admissions to emergency care centres with acute coronary syndromes remain one of the principal burdens on healthcare systems in the Western world. Early pharmacological treatment in these patients is crucial, lessening the impact on both morbidity and mortality, with the cornerstone of management being antiplatelet agents. While aspirin and clopidogrel have been the drugs of choice for nearly a decade, an array of newer, more potent antiplatelet agents are now available or in late stage development. Data are rapidly gathering suggesting these agents have superior anti-ischaemic properties, improving patient outcomes, but that for some agents increased vigilance and appropriate patient selection may be necessary to guard against bleeding complications. In this review, the authors aim to deliver an overview of the changing field of antiplatelet therapy and provide information about the relative risks and benefits of these newer agents, many of which will be entering widespread clinical use imminently.
Related Concept Videos
01:26Angina IV: Management
01:26Acute Coronary Syndrome V: Nursing Management
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...